FDA panel recommends drug strictly for African-Americans

Share this article:
The FDA moved one step closer to approving the first drug marketed to a specific ethnic group yesterday when an agency panel recommended that NitroMed's BiDil be marketed for strictly treating black people with heart failure.
The drug has  raised questions about how marketing, regulatory and political considerations play a role in new drug development, with critics of NitroMed saying the company has managed the regulatory system and patent law, along with historical inequities to drive its product to market.
Share this article:
You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.